theglobeandmail.comOCT 102 min read$GMAB

Genmab (GMAB) Receives a Buy from Truist Financial

Analysts from Truist Financial and Bank of America maintained Buy ratings on Genmab (GMAB), with price targets of $45.00 and DKK2,850.00, respectively. Genmab reported Q2 revenue of $1.16B and net profit of $303M, up from $924.81M and $335.93M in the same period last year.

Original reporting

theglobeandmail.com

Published Oct 10, 2026, 2:51 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 10, 2026, 3:13 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Genmab (GMAB) Receives a Buy from Truist Financial — source image — Source · theglobeandmail.com

Decision brief

The 30-second read

$GMABBullishLow

Why it matters

Maintaining a Buy rating with a $45 target may provide slight upside, but the earnings data are already public.

Market read

Provides a modest analyst endorsement for GMAB; limited broader market effect.

What to watch

Potential headwinds from upcoming regulatory reviews and competitive pipeline not discussed.

Relevance 4/10Novelty 2/10Timing: none

Background

Analyst coverage update following Genmab's Q2 earnings release.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$GMABBullishMedium confidence

Context

Truist analyst maintains Buy rating with $45 price target and recaps Genmab's Q2 earnings (revenue $1.16B, net profit $303M).

Expected impact

slight upward pressure as the market prices in the maintained Buy rating and price target

Evidence & confidence

Buy rating and price target suggest confidence in earnings, but numbers are already public, limiting impact.

Market effects

Sector

Reinforces positive outlook for biotech sector peers as earnings beat expectations.

Regional

Limited impact on European markets; Genmab is a Danish company with US ADR.

Global

Minor, confined to investors tracking biotech earnings and analyst upgrades.

Counterpoint

What could challenge this read

The price target may be overly optimistic given modest profit decline year‑over‑year.

Key entities

company
Genmab
Danish biotech firm listed on Nasdaq as GMAB.
financial_institution
Truist Financial
Brokerage firm providing the analyst rating.

Read at source ← All news

OCT 20

$GMABMed

Morgan Stanley initiates Genmab stock coverage with Equalweight rating

Morgan Stanley initiated coverage on Genmab (GMAB) with an Equalweight rating and a $42 price target. The stock trades at $38.50 with a $22.81B market cap. Darzalex contributed 65% of 2025 revenue, with royalties ending in 2029-2031. Morgan Stanley models revenue peaking at $8.63B in 2030 before declining. Genmab reported Q2 2026 earnings of $4.91 per share, exceeding estimates, and raised 2026 revenue guidance to DKK 4.3B-4.5B. Other analysts raised price targets to $50 and $54.

investing.com2 min

OCT 19

$GMABMedAI 8/10

Weekly Recap: EPCORE DLBCL-2 positive results and DARZALEX Q3 2026 sales

Genmab reported that epcoritamab plus R-CHOP reduced the risk of progression or death by 51% compared to R-CHOP alone in the Phase 3 EPCORE DLBCL-2 trial. The company plans to present these results and share them with regulators. Additionally, Genmab announced Q3 2026 net sales of $4.239B for DARZALEX, generating royalties for the company.

tradingview.com1 min

OCT 19

$ZNTLMedAI 8/10

Zentalis Pharmaceuticals reports 15.8-month survival

Zentalis Pharmaceuticals (ZNTL) reported Phase 2 data showing 15.8-month median survival in Cyclin E1-positive ovarian cancer patients treated with azenosertib. The study lacked a chemotherapy control group. Shares fell 4.91% to $2.13 before the announcement. Zentalis expects topline DENALI Part 2 results in 1H 2027 and has sufficient cash to fund operations into late 2027.

mugglehead.com2 min

OCT 14

$ONCYMed

Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda

Global cancer drug spending reached $252B in 2024 and is forecast to exceed $400B by 2028, with the U.S. accounting for 46%. Several companies, including Oncolytics Biotech (ONCY), Revolution Medicines (RVMD), Eli Lilly (LLY), Genmab (GMAB), and Exelixis (EXEL), are advancing treatments for colorectal and pancreatic cancers. Oncolytics reported accelerating enrollment in a colorectal cancer study, while Revolution Medicines received FDA approval for a pancreatic cancer drug.

prnewswire.com3 min

OCT 13